MONTREAL, September 25th, 2023 – Replicor Inc. announced the presentation of new data describing the direct acting activity of REP 2139 against HDV replication at the 2023 International Molecular Biology of HBV meeting, held from September 19-23, 2023 in Kobe, Japan (see here).
This new data, generated in the lab of Dr. Massimo Levrero at the Lyon Hepatology Institute / INSERM U1052 (Lyon, France), provides for the first time the direct observation of the inhibition of HDV replication by REP 2139 in tissue culture. This evolving dataset demonstrates a 10-fold reduction in HDV RNA and disruption of the interaction between HDV RNA and the hepatitis delta antigen (HDAg) with a single dose of REP 2139. These effects occur prior to the envelopment of the HDV viral core (ribonucleoprotein) with HBsAg and are independent and additional to the previously described HBsAg-dependent effects on HDV envelopment and secretion. The presentation can be accessed here.
Dr. Andrew Vaillant, CSO of Replicor commented, “A distinct and direct acting activity of REP 2139 was evident in our first phase II study of REP 2139 in HDV (see here) and from later direct interactions observed between the small and large isoforms of HDAg and REP 2139 (see here). This new data is consistent with these earlier observations and provides an important mechanistic framework for a detailed dissection of the direct acting antiviral effects of REP 2139 against HDV. These data also highlight the unique properties of REP 2139 as a dual function agent capable of targeting both HBV and HDV infections.”
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV infection. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.